MetaCap

Arbutus Biopharma (ABUS) vs Nuvectis Pharma (NVCT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Nuvectis Pharma (NVCT) has outperformed Arbutus Biopharma (ABUS) over the past year, gaining 218.9% versus a loss of 6.7%. Nuvectis Pharma is the larger company by market cap ($666.8 million vs $616.2 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ABUS-6.73%NVCT+218.91%
+388%+177%-34%
Nov 21, 20251 yearNov 20, 2026
ABUS+33.11%NVCT+496.62%
+776%+347%-82%
Jan 31, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ABUS versus NVCT key metrics
MetricABUSNVCT
Share price$4.02$19.39
Market cap$616.24M$666.80M
1-day change-1.23%-2.27%
YTD return-16.42%+156.82%
1-year return-6.73%+218.91%
5-year return+28.43%—
P/E ratio (TTM)3.59—
EPS (TTM)$1.12$-2.00
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$14.08M—
Revenue growth (YoY)+128.21%—
Net income (latest FY)$-33.50M$-26.44M
Operating margin-270.96%—
Net margin-237.88%—
52-week high$5.45$29.28
52-week low$3.50$5.77
Distance from 52-week high-26.24%-33.77%
Analyst consensusnonenone
Avg. price target upside+32.34%+82.57%
Average volume4.98M206.37K
Shares outstanding153.29M34.39M
Employees1919
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • NVCT has outperformed ABUS by 225.6 percentage points over the past year.

About Arbutus Biopharma

ABUS stock →

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1.

Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees

About Nuvectis Pharma

NVCT stock →

Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees

ABUS vs NVCT FAQ

Which is bigger, Arbutus Biopharma or Nuvectis Pharma?

Nuvectis Pharma (NVCT) is larger, with a market capitalization of $666.80M compared with $616.24M for Arbutus Biopharma (ABUS).

Which stock has performed better over the past year, ABUS or NVCT?

NVCT returned +218.91% over the past 12 months, compared with -6.73% for ABUS (price return, excluding dividends). Past performance does not predict future results.

Are Arbutus Biopharma and Nuvectis Pharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons